SEC Form 4 · accession 0001358403-17-000131
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ken Moseley
Officer — Sr. VP and General Counsel
Period of report
Jul 3, 2017
Accepted (ET)
Jul 6, 2017 · 4:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $11.70 | Jul 3, 2017 | A | 26,250 | A | — | Jul 2, 2027 | Common Stock | 26,250 | 26,250 | D |
| Stock Option (right to buy)F2,F1 | $11.70 | Jul 3, 2017 | A | 42,000 | A | — | Jul 2, 2027 | Common Stock | 42,000 | 42,000 | I |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on January 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F2The Reporting Person's spouse is Annemarie Moseley, Consultant to Bellicum, formerly COO/EVP Clinical Development. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.